Literature DB >> 11027627

Adenosine: A partial agonist of the growth hormone secretagogue receptor.

R G Smith1, P R Griffin, Y Xu, A G Smith, K Liu, J Calacay, S D Feighner, C Pong, D Leong, A Pomés, K Cheng, L H Van der Ploeg, A D Howard, J Schaeffer, R J Leonard.   

Abstract

The growth hormone secretagogue receptor (GHS-R) is involved in the regulation of pulsatile GH release. However, until recently, natural endogenous ligands for the receptor were unknown. We fractionated porcine hypothalamic extracts and assayed fractions for activity on HEK293 cells expressing GHS-R and aequorin. A partial agonist was isolated and identified using microspray tandem mass spectrometry as adenosine. GHS-R activation by adenosine and synthetic adenosine agonists is inhibited by the GHS-R selective antagonists L-765,867, D-Lys(3)-GHRP-6, and by theophylline and XAC. Cross desensitization of the GHS-R occurs with both MK-0677 and adenosine. Ligand binding and site directed mutagenesis studies show that adenosine binds to a binding site that is distinct from the previously characterized MK-0677 and GHRP-6 binding pocket. We propose, that adenosine is a physiologically important endogenous GHS-R ligand and speculate that GHS-R ligands modulate dopamine release from hypothalamic neurons. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027627     DOI: 10.1006/bbrc.2000.3610

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Deletion of ghrelin impairs neither growth nor appetite.

Authors:  Yuxiang Sun; Saira Ahmed; Roy G Smith
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

2.  Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway.

Authors:  Delphine Mousseaux; Lionel Le Gallic; Joanne Ryan; Catherine Oiry; Didier Gagne; Jean-Alain Fehrentz; Jean-Claude Galleyrand; Jean Martinez
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

Review 3.  Growth hormone secretagogue receptor family members and ligands.

Authors:  R G Smith; R Leonard; A R Bailey; O Palyha; S Feighner; C Tan; K K Mckee; S S Pong; P Griffin; A Howard
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

4.  Receptor-specific crosstalk between prostanoid E receptor 3 and bombesin receptor subtype 3.

Authors:  Yan Zhang; Yanfang Liu; Lehao Wu; Chao Fan; Zhiwei Wang; Xiuli Zhang; Amal Alachkar; Xinmiao Liang; Olivier Civelli
Journal:  FASEB J       Date:  2018-01-22       Impact factor: 5.191

5.  Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor.

Authors:  Yuxiang Sun; Pei Wang; Hui Zheng; Roy G Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-18       Impact factor: 11.205

Review 6.  Purinergic signalling in endocrine organs.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

Review 7.  Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network.

Authors:  Doug Redelman; Lisbeth A Welniak; Dennis Taub; William J Murphy
Journal:  Cell Immunol       Date:  2008-03-04       Impact factor: 4.868

Review 8.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

Review 9.  Targeting the ghrelin receptor: orally active GHS and cortistatin analogs.

Authors:  Romano Deghenghi; Fabio Broglio; Mauro Papotti; Giampiero Muccioli; Ezio Ghigo
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

Review 10.  Regulation of ghrelin secretion and action.

Authors:  Jesus P Camiña; Marcos C Carreira; Dragan Micic; Manuel Pombo; Fahrettin Kelestimur; Carlos Dieguez; Felipe F Casanueva
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.